Transplant International

DON’T FORGET! To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

🏥machine_perfusion (#MP) is increasingly being utilised for #DCD liver transplants. In this #UNOS study from 2016 to 2025, we showed an accelerated, 7.8-fold increase in the use of DCD livers from donors ≥60 in the #MP_era, with a reduction of the median #waitlist #time from 112 to 62 days, and acceptable early graft survival. @_ILTS_ @ESOTtransplant @Transpl_Int frontierspartnerships.org/journals/trans…

Alors que la cérémonie @NobelPrize se tiendra aujourd'hui, notre commission scientifique a eu le privilège d’être invitée par @Transpl_Int à honorer les 3 lauréats du prix de Physiologie ou Médecine 2025, Mary Brunkow, Fred Ramsdell et Shimon Sakaguchi. transplantation-francophone.org/actualites/pri…

🚨 New paper alert in @Transpl_Int 🔑 Evolving Trends in Organ Donation and Transplantation Rates Across Muslim Majority Countries 🖍️ @IPATransplant_ ‼️ Under-reported data/⬇️ donation/transplant activity/socio-economic versus religious barriers. 🔗 frontierspartnerships.org/journals/trans…

RT @TIPLosAngeles: We are extremely excited to see our "Five Years Follow-up of Imlifidase Desensitized Kidney Transplant Recipients" publi…

The case for age-aligned kidney allocation in the US @Transpl_Int @ASTSChimera @ttsorg @ESOTtransplant frontierspartnerships.org/journals/trans…

Need a reminder about why the 2025 Nobel Prize in Physiology or Medicine is so important for Transplantation? 📖 Read the News & Views article by Julien Zuber and Hannah Kaminski (@hKminski) in @Transpl_Int now 👉 frontierspartnerships.org/journals/trans… @ESOTtransplant

🎉 Congrats to @Transpl_Int for an outstanding session at #ESOTcongress—highlighting top research! 👏 Kudos to @DrSamratRay & @shwaartz for their study on managing duodenal leaks after pancreas TX suggesting salvage strategies 🛟 may be safe. 📖 doi.org/ptvz

Be careful!!

STAY TUNED!! To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

REMEMBER!!! To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

WHAT’S NEW? To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

Check out the @Transpl_Int February issue 🤩

REMEMBER! To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

DID YOU DO IT? To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

DON’T FORGET! To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

DON’T FORGET! To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected! Linkedin: shorturl.at/2plxb Instagram: shorturl.at/QLhJx Bluesky: shorturl.at/IOMyF

📖 Read the full publication & see the visual abstract: Frontiers Publishing Partnerships | Desensitization With Imlifidase for HLA-Incompatible Deceased Donor Kidney Transplantation: A Delphi International Expert Consensus Register here: go.esot.org/ti_jc17march (6/6)

📅 Mark your calendar! 🗓 March 17, 2025 – 17:00 CET 📍 Live Zoom Session (45 min) 👥 Open to all, esp. young transplant professionals! Don’t miss this chance to engage with top experts on a cutting-edge topic! Register here: go.esot.org/ti_jc17march (5/6)

📢 Join our next @Transplant International Journal Club! We’ll dive into a Delphi consensus on imlifidase for HLA-incompatible kidney transplantation in highly sensitized patients. 🏥💉 #Transplantation #KidneyTransplant (1/6) Register here: go.esot.org/ti_jc17march